![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
ValiRx plc is a therapeutics and diagnostics company developing an integrated approach to the diagnosis, treatment and prognosis of cancer through its two subsidiaries; ValiPharma and ValiBio. Over 95% of cellular DNA is tightly packaged into a complex structure called chromatin, with only 1% available to be read by cell‘s machinery. ValiRx‘s two proprietary technology platforms exploit this epigenomic structure. ValiBio is developing low-cost, rapid, high-throughput, noninvasive screening tests for the early detection, differential diagnosis and prognosis of cancer using its patented Hypergenomics™ and Nucleosomics™ technology. Its therapeutics subsidiary, ValiPharma, is developing novel gene-silencing therapeutics based on its GeneICE™ technology platform, which works by repackaging specific open areas of DNA, resulting in targeted gene deactivation. HyperGenomics and GeneICE are synergistic but independent business areas based on the company‘s core patent portfolio. ValiRx intends to facilitate early, optimal personalized treatment regimes by correlating ‘hypersensitive‘ site profiles within the genome to specific types of cancer.
Financial & competing interests disclosure
Both authors work for ValiRx plc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.